Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 2 of 16.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-000590-12 Sponsor Protocol Number: CRAD001HDE53 Start Date*: 2015-09-03
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving either RAD001 (everolimus) plus re...
    Medical condition: liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10050434 Prophylaxis against liver transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003795-13 Sponsor Protocol Number: CRAD001M2305 Start Date*: 2014-12-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301
    Medical condition: Subependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004850 10045138 Tuberous sclerosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024515-13 Sponsor Protocol Number: VU-007 Start Date*: 2011-03-22
    Sponsor Name:VU University Medical Center
    Full Title: Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
    Medical condition: Metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003736-77 Sponsor Protocol Number: E7080-A001-216 Start Date*: 2023-03-28
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Medical condition: Recurrent and Refractory Solid Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000769-19 Sponsor Protocol Number: CBEZ235Z2401 Start Date*: 2012-10-25
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors
    Medical condition: Adult patient in advanced pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Completed) IT (Completed) FR (Completed) NL (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003069-14 Sponsor Protocol Number: CRAD001H2305 Start Date*: 2012-06-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, multi-center, single arm, prospective study to evaluate renal function, efficacy, safety and tolerability of everolimus in combination with reduced exposure cyclosporine or tacrolimus i...
    Medical condition: Paediatric liver transplant recipients with age equal/greater to 1 month and younger than 18 years.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10024716 Liver transplantation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SE (Temporarily Halted) DE (Completed) ES (Completed) GB (Completed) DK (Completed) IT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005116-12 Sponsor Protocol Number: CRAD001C2428 Start Date*: 2008-03-20
    Sponsor Name:Technical University of Munich
    Full Title: Phase II study of the mTOR-Inhibitor EVEROLIMUS as maintenance therapy in patients aged over 60 years with Mantle Cell Lymphoma (MCL) after first, second, third or fourth line chemotherapy New ...
    Medical condition: Strategies to prolong remission duration in elderly patients with MCL are urgently needed. The effects of Rapamycin derivates on MCL cells in vitro and the evolving in vivo data support the furthe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002419-14 Sponsor Protocol Number: IRST189.04 Start Date*: 2015-09-02
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PRE...
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004856-12 Sponsor Protocol Number: Ever_cyto_Treg Start Date*: 2013-03-12
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Nephrologie
    Full Title: Changes of cytokines and regulatory T cells in renal transplant recipients after switch to the mTOR inhibitor Everolimus. A Single center trial, non-blinded, non-randomized.
    Medical condition: organ transplant
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001945-32 Sponsor Protocol Number: knoop1 Start Date*: 2006-11-13
    Sponsor Name:ULB Erasme
    Full Title: Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.
    Medical condition: Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000726-66 Sponsor Protocol Number: GETNE1206 Start Date*: 2014-10-08
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)
    Full Title: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by ...
    Medical condition: advanced progressive pNETs
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed) ES (Completed) DK (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-001539-21 Sponsor Protocol Number: CRAD001ADE36 Start Date*: 2011-09-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 2-arm, prospective, randomized, controlled, open-label, 12 month Phase III trial to evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen co...
    Medical condition: lung transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10050433 Prophylaxis against lung transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023183-40 Sponsor Protocol Number: CSOM230I2201 Start Date*: 2011-06-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu...
    Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003951-72 Sponsor Protocol Number: GOIRC02/2014 Start Date*: 2015-03-05
    Sponsor Name:Gruppo Oncologico Italiano Ricerca Cancro (GOIRC)
    Full Title: Phase II randomized multicenter study of Everolimus as maintenance therapy for metastatic neuroendocrine carcinoma with pulmonary or gastroenteropancreatic origin.
    Medical condition: The aim of this study is to evaluate the activity of a maintenance therapy with everolimus 10 mg daily in patients with stable disease, partial response or complete response after 6 cycles of indu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001951-20 Sponsor Protocol Number: UCL/06/053 Start Date*: 2008-03-12
    Sponsor Name:University College London
    Full Title: A phase I and randomised phase II study of Docetaxel and RAD001 (Everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck
    Medical condition: Locally advanced or metastatic squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063569 Metastatic squamous cell carcinoma LLT
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024381-21 Sponsor Protocol Number: CRAD001A2314 Start Date*: 2011-07-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination c...
    Medical condition: Prevention of acute rejection in paediatric recipients of a renal transplant
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Completed) DE (Completed) NO (Completed) IT (Completed) Outside EU/EEA SE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002872-17 Sponsor Protocol Number: CSOM230DIC03 Start Date*: 2013-06-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and th...
    Medical condition: Neouroendocrine carcinoma of the lung and thymus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025064 Lung carcinoma LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DK (Completed) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004139-62 Sponsor Protocol Number: CRAD001JES13 Start Date*: 2014-01-02
    Sponsor Name:Novartis Farmacéutica S. A.
    Full Title: A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the f...
    Medical condition: Estrogen receptor or progesterone receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000073-23 Sponsor Protocol Number: CRAD001YIC04 Start Date*: 2012-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrin...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) NL (Completed) SE (Completed) NO (Completed) ES (Completed) DK (Completed) FI (Completed) BE (Completed) CZ (Prematurely Ended) IT (Completed) HU (Completed) IE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-005640-34 Sponsor Protocol Number: DFIDM-1501 Start Date*: 2016-12-29
    Sponsor Name:CHIESI FARMACEUTICI S.P.A.
    Full Title: Envarsus® tablets administered once daily in combination with everolimus in elderly de-novo kidney transplant recipients: open-label, multicentre, single-arm, pharmacokinetic and clinical study
    Medical condition: Prophylaxis of organ transplant rejection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:45:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA